The benefit-risk assessment compares the expected or observed therapeutic benefits of a medicinal product or medical device in a structured manner with its risks and the remaining uncertainties. The question is never generally whether a product is “good”, but always what the ratio of benefit to risk is for a specific indication, population and application context. As the supporting criterion for authorization and conformity decisions, it is continually updated throughout the entire product lifecycle.
Assessment during the authorization procedure and post-market entry
Prior to the authorization of a medicinal product, quality, safety and efficacy are not assessed separately, but in context. The benefit side includes clinically relevant endpoints, extent and duration of the effect, robustness of the evidence and the available treatment alternatives; the risk side includes nature, frequency, severity, predictability and treatability of adverse effects. How heavily a risk weighs depends on the severity of the disease: a clear therapeutic benefit can bear a serious but controllable risk, a minor benefit cannot. Since both sides are assessed relatively, the reference to comparison therapy and standard of care is part of it.
In addition to the known risks, the uncertainties of the data must be explicitly stated: a limited sample size, a short follow-up period, missing data for special patient groups or inconsistent subgroup results. Frequently, submissions fail due to an unstructured narrative that describes benefits and risks but reveals neither a traceable weighting nor a justification for the conclusion. A coherent chain of argumentation is expected, which explains, for example, why a safety risk remains acceptable given a high medical need or effective risk minimization measures.
The assessment does not end with the authorization. Spontaneous reports, literature, registries and safety studies specify risks or alter the transferability of an observed benefit. The Periodic Safety Update Report provides an integrated analysis of new findings at fixed intervals against the background of the accumulated data, while the risk management plan records risks, missing information and minimization measures. Consequences can be changes to the product information, obligations for further studies or, in the extreme case, suspension and revocation of the authorization; conversely, with every notification of change, it must be assessed whether new indications or safety findings shift the balance.
Methodological approaches and special features for medical devices
The assessment is predominantly qualitative, supported by clinical plausibility, consistency of the data and clinical relevance. For complex decisions, quantitative procedures are available: structured benefit-risk models, multi-criteria decision analysis or weighted benefit-risk tables, which explicitly contrast individual criteria. What determines verifiability is less the method than the disclosure of assumptions, sensitivity analyses and a consistent handling of uncertainty. If essential gaps remain, a conditional approval with the obligation to submit missing data later may be an option.
For medicinal products, the benefit also includes quality of life, therapy adherence and patient-reported endpoints. For medical devices, Article 2 number 24 of Regulation (EU) 2017/745 defines the benefit-risk determination as the analysis of all assessments of benefit and risk of possible relevance for the use of the device for the intended purpose, when used in accordance with the intended purpose given by the manufacturer. Here, the clinical benefit in the care context, the safety performance over the product lifetime and usability carry more weight. This is documented via the clinical evaluation according to Article 61 and Annex XIV including post-market clinical follow-up; the determination is verified in the conformity assessment procedure by the notified body.
Distinction from benefit assessment in reimbursement law
The regulatory benefit-risk assessment must not be confused with the benefit assessment of reimbursement law. It solely answers whether a favorable benefit-risk ratio exists and continues to exist for the intended application, and thus belongs to authorization or conformity assessment, surveillance and pharmacovigilance. Any available safety and efficacy information including experience from care practice is taken into account.
The benefit assessment according to Section 35a SGB V, on the other hand, serves social law and health economic purposes: it evaluates an added benefit compared to an appropriate comparator therapy and does not replace the authorization decision. A preparation can therefore be authorized, while added benefit, comparator therapy and reimbursement conditions are decided separately. Equating both levels regularly leads to false expectations in trial planning, dossiers and communication.
Relevance for clinical trials
The evidence for every benefit and risk statement is generated in clinical trials, which is why this assessment already shapes the development strategy. Endpoints, safety parameters, target population, predefined subgroups, observation duration and the handling of missing values must fit the decision to be justified later. Article 28 of Regulation (EU) No 536/2014 already requires for the authorization of a clinical trial that the anticipated benefits justify the foreseeable risks and inconveniences and that compliance with this condition is constantly monitored. Ongoing safety data lead to adapted inclusion criteria, additional controls or a reassessment by an independent committee.
Full-service CROs such as Mediconomics support in predictably generating the data needed for this determination: through study design and alignment of the protocol with risk management, through data management and biostatistical analysis of the efficacy and safety endpoints, through the medical review of incoming safety information and through medical writing for study reports and submission documents. Thus, a consistent line of argument remains visible from the analysis to the periodic safety reports.
Frequently Asked Questions (FAQ)
Does the benefit-risk assessment end with the authorization?
No, it continues with every new safety, efficacy and application information. Periodic safety reports, signal evaluations and post-authorization studies can shift the result.
What is the purpose of the risk management plan in this assessment?
It records important identified and potential risks as well as missing information and determines with which activities they will be further characterized or minimized. The requirements for content and format are described in the GVP module V.
Does a favorable benefit-risk ratio automatically mean an added benefit?
No. One is a criterion for authorization and regulatory surveillance, the other is the result of an independent assessment for reimbursement decisions.
Regulatory references
- Regulation (EC) No 726/2004 – authorization and supervision of centrally authorized medicinal products for human use.
- Directive 2001/83/EC, Title IX Pharmacovigilance – pharmacovigilance system, signal detection and ongoing surveillance.
- Regulation (EU) No 536/2014, Article 28 – benefit-risk condition for the authorization of clinical trials.
- EMA Guideline on good pharmacovigilance practices, Module VII Periodic safety update report – integrated benefit-risk analysis in the PSUR.
- Regulation (EU) 2017/745, Article 2 number 24 and Annex XIV – benefit-risk determination and clinical evaluation for medical devices.